AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04278846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depofoam bupivacaine
Description: The study drug Depofoam bupivacaine will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
Study NCT04278846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine hydrochloride (HCl)
Description: The study drug bupivacaine HCl will be administered into the right and/or left breast of each patient 30 minutes prior to the creation of the subpectoral muscle pocket.
Study NCT04115202 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar arthrodesis
Description: two approaches anterior versus posterior, optimally by leaving physicians free to use them as they do daily without modifying their procedures
Study NCT03159455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335
Description: Duration - 28 days
Study NCT03159455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Duration - 28 days
Study NCT02366546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBI-1301
Description: TBI-1301(5\*10\^8 or 5\*10\^9) is administered.
Study NCT03989232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
Study NCT03989232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide injected subcutaneously (s.c., under the skin) once-weekly. Participants will keep taking their pre-study diabetes tablets throughout the study.
Study NCT03989232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Semaglutide placebo injected once-weekly from week 13 to week 40.
Study NCT03213587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
Study NCT05202444 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteotomy using piezoelectrical device
Description: osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla.
Study NCT05202444 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteotomy using piezoelectrical device
Description: osteotomy were utilized using piezoelectric from device (Woodpeker) with its internal irrigation system. We used US2 tip using the maximum bone cutting program and maximum irrigation program for lateral maxillary wall osteotomy and USIR tip for the posterior maxillary wall osteotomy.~The pterygoid osteotome was placed between the tuberosity and pterygoid plates while the hamulus is palpated palatally with the index finger to guide the osteotome direction preventing palatal perforation.With the pterygoid osteotome still in position, we used a thin osteotome to complete the osteotomy of the posterior wall of the maxilla.
Study NCT01645241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropins plus GnRH antagonists
Study NCT01645241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix
Study NCT01473459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVM (In Vitro Maturation) Treatment
Description: There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
Study NCT01473459 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF (In Vitro Fertilization) Antagonist Protocol
Description: The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
Study NCT01196286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multifamily Group Psychoeducation (MFG)
Description: Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
Study NCT01196286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifamily Group Psychoeducation (MFG)
Description: Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
Study NCT01196286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR)
Description: Computer exercises designed to improve cognitive functioning (3hr/wk).
Study NCT01634802 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: EMR Only
Description: Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
Study NCT01634802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR+CDSS
Description: Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
Study NCT03379597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifico (Live combined bifidobacterium,Lactobacillus and Enterococcus capsules, Oral)
Description: Bifico 840mg Bid
Study NCT03696290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aztreonam lysine
Description: Nebulised aztreonam lysine 75mg
Study NCT03696290 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebulised lactose monohydrate 5mg
Study NCT00810147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 25 mg, once daily, 24 weeks
Study NCT00810147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 50 mg, once daily, 24 weeks
Study NCT00810147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 100 mg, once daily, 24 weeks
Study NCT00810147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-708163
Description: Capsules, Oral, 125 mg, once daily, 24 weeks
Study NCT00810147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 24 weeks
Study NCT03379597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber
Description: dietary fiber compound powder 30g bid
Study NCT00741013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin pill and placebo IV
Description: lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Study NCT00741013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo pill and recombinant human activated protein C IV
Description: placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Study NCT00741013 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Endotoxin
Description: Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
Study NCT00741013 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Endotoxin
Description: Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
Study NCT02754375 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rTMS
Study NCT00694902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK610677
Description: GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
Study NCT01679990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD Low dose
Study NCT02133781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® 2009-2010 Formula
Description: This vaccine is given intramuscularly
Study NCT02133781 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluMist® 2009-2010 Formula
Description: This vaccine is given intranasally
Study NCT00988273 — intervention group
Intervention type: DEVICE
Intervention: Confocal endomicroscopy
Description: Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
Study NCT00988273 — intervention group
Intervention type: DEVICE
Intervention: Confocal endomicroscopy
Description: Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
Study NCT03536234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate depot
Description: 3.75 mg triptorelin depot (monthly injections). 3 doses in total
Study NCT00532298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]
Description: Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
Study NCT00532298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]
Description: Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
Study NCT00532298 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix [NH 2006/07 season]
Description: Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
Study NCT00532298 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix [NH 2007/08 season]
Description: Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
Study NCT03282929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 1
Description: A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
Study NCT03282929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 2 Group 1
Description: 300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
Study NCT03282929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2 group 2
Description: 500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
Study NCT03282929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 2 group 3
Description: 300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
Study NCT02366546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Study NCT03282929 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Part 2 Group 4
Description: 300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
Study NCT01771237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPeeps Manualized Group Intervention
Description: Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
Study NCT01771237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Sexual Health Education
Description: Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
Study NCT02366546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
Study NCT04355819 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure timing
Description: When patients are told that a hernia was present on the CT scan
Study NCT03478800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Each treatment would take approximately 15-20 minutes and would take place immediately after practice for a total of five treatments. The needles are standard (0.2mm diameter #36 gauge 1 inch stainless steel) and during each treatment, 3-6 needles would be placed in the lower extremity in any of the following muscle groups: quadriceps, hamstrings, anterior tibialis, gastrocnemius-soleus complex, medial head of the gastrocnemius, peroneal muscles, or iliotibial band. The athletes would complete brief pre- and post-treatment surveys.
Study NCT00650403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine hydrochloride 40 mg tablet
Description: 40mg, single dose fed
Study NCT00650403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paxil® 40 mg Tablet
Description: 40mg, single dose fed
Study NCT01391936 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tension Band Wiring
Description: AO technique of TBW for fixation of fracture.
Study NCT01679990 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PLX-PAD high doses
Study NCT01679990 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Double Placebo
Study NCT01679990 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: high dose +Placebo
Study NCT00985114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: EndoBarrier implant
Study NCT00985114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet + Lifestyle Counseling
Description: Multidisciplinary lifestyle and nutritional counseling
Study NCT00985114 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet + Lifestyle Counseling
Description: Multidisciplinary lifestyle and nutritional counseling
Study NCT01794221 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stitches and skin adhesive
Description: In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
Study NCT01794221 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: stitches only
Description: standard of care
Study NCT02564627 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-applied patch
Description: An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
Study NCT02564627 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional procedure
Description: PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
Study NCT02564627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 1200 Kcal/day diet
Description: A 1200 Kcal/day diet will be prescribed.
Study NCT02564627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1200 Kcal/day diet
Description: A 1200 Kcal/day diet will be prescribed.
Study NCT02564627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1200 Kcal/day diet
Description: A 1200 Kcal/day diet will be prescribed.
Study NCT01437982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loteprednol Etabonate
Description: Ocular administration of study drug. at least once within any indication of the label.
Study NCT01437982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Ocular administration of study drug. at least once within any indication of the label.
Study NCT01391936 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plate fixation
Description: Patients in this arm will receive plate and screw fixation of their olecranon fracture.
Study NCT02581735 — intervention group
Intervention type: OTHER
Intervention: Patients with haemophilia
Description: Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.~At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale .
Study NCT04153526 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood samples will be obtained during routine clinical visits. Ideally, two 9mL blood samples (or equivalent volume) will be collected into EDTA or other appropriate blood collection tube at each time point except at baseline, where three EDTA 9mL tubes and one of 2.6mL (for study of whole blood) will be collected.
Study NCT01663064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment (Zenith® p-Branch™ endovascular graft)
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study NCT02298400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue® Oasys® Lenses (senofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours
Study NCT02298400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 30-Day Bausch + Lomb PureVision (balafilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours
Study NCT02298400 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clariti® 1-Day (Somofilcon A)
Description: Contact lenses placed in each eye during the day for about 8 hours
Study NCT01726829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MD-Logic Artificial Pancreas (MDLAP) system
Study NCT01726829 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sensor augmented pump therapy
Study NCT01805479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: the active arm will be asked to perform 60% of maximum heart rate
Study NCT01805479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: stretching and flexibility program
Description: stretching and flexibility program for the Placebo Comparator Arm
Study NCT02630511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol consists of inhaling 0 (empty capsule acting as a placebo), 5, 10, 20, 40, 80, 160, 160, and 160 mg mannitol, resulting in a maximum cumulative dose of 635 mg
Study NCT02630511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methacholine
Description: Methacholine consists of inhaling 0.0625 mg/mL, 0.25 mg/mL, 1 mg/mL, 4 mg/mL, and 16 mg/mL
Study NCT04153526 — intervention group
Intervention type: PROCEDURE
Intervention: Surplus Tumour Tissue sample collection from surgery
Description: In surgical patients, lung tumour samples and normal lung tissue will be obtained from surplus tissue removed at the time of surgery. No extra procedures (biopsies or surgeries) are requested for the study.
Study NCT04153526 — intervention group
Intervention type: OTHER
Intervention: Collection or archival tumour tissue (If available)
Description: Where available surplus tumour and normal tissue from archival tissue will be collected for analysis.
Study NCT02274363 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque-type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
Study NCT03429894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Drug eluting stent implant
Study NCT01853319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73- 4506)
Description: 160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)